<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828709</url>
  </required_header>
  <id_info>
    <org_study_id>NL5693501816</org_study_id>
    <nct_id>NCT02828709</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of IRE for SRMs</brief_title>
  <official_title>The Safety and Feasibility of Irreversible Electroporation for the Ablation of Small Renal Masses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Prof. M.P. Laguna Pes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Angiodynamics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irreversible Electroporation (IRE) is an emerging technique delivering electrical pulses to
      ablate tissue, with the theoretical advantage to overcome the main shortcomings of
      conventional thermal ablation. Recent short-term research showed that IRE for the ablation of
      renal masses is a safe and feasible treatment option. In an ablate and resect design,
      histopathological analysis 4 weeks after radical nephrectomy demonstrated that IRE targeted
      renal tumors were completely covered by ablation zone. In order to develop a validated
      long-term IRE follow-up study, it is essential to obtain clinical confirmation of the
      efficacy of this novel technology. Additionally, follow-up after IRE ablation obliges
      verification of a suitable imaging modality. The objectives of this study are the clinical
      efficacy and safety of IRE ablation of renal masses and to evaluate the use of
      cross-sectional imaging modalities in the follow-up after IRE in renal tumours.

      This is a prospective, human, in-vivo study among 20 patients presenting with solid enhancing
      SRM on cross sectional imaging suspect for renal cell carcinoma (RCC). Preoperatively,
      imaging is required through Magnetic Resonance Imaging (MRI), Contrast-enhanced ultrasound
      (CEUS) and contrast-enhanced Computed Tomography (CT). Furthermore, serum creatinine levels
      and VAS scores are obtained. A biopsy of the SRM will be performed in preoperative setting.
      IRE ablation will be performed using CT-guidance and ablation success will be measured
      directly after the ablation through contrast-enhanced CT. Device related adverse events (AE)
      will be registered using the Common Terminology Criteria for Adverse Events (CTCAE) version
      4.0 guideline. One week post ablation only CEUS and MRI will be performed to limit exposure
      to ionizing radiation. At 3 months, 6 months and 12 months post ablation CEUS, MRI and CT
      will be performed. Additionally, at these time points serum creatinine levels and VAS scores
      will be obtained, and quality of life will be assessed through SF-36 questionnaires. Residual
      and recurrent disease will be assessed through tissue enhancement on cross sectional imaging.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety IRE ablation procedure (evaluating device and procedural adverse events using CTCAE v4.0)</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the safety and feasibility of IRE ablation of small renal masses (≤ 4cm), by evaluating device and procedural adverse events using CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy ((non‐)presence of tumour enhancement on cross‐sectional imaging post IRE)</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the clinical efficacy of IRE ablation of small renal masses (≤ 4cm), assessed by calculating recurrence and residual disease at follow‐up, measured through the (non‐)presence of tumour enhancement on cross‐sectional imaging post IRE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross sectional imaging post ablation</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the use of CT, MRI, and CEUS in the imaging of ablation success, extend of the ablation zone, 1 week, 3 months, 6 months, and 1 year post IRE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the effect of RE ablation of small renal masses (≤ 4cm) on the renal function, measured by serum creatinine levels and estimated Glomerular Filtration Rate (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average length of hospital stay</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the effect of IRE ablation of small renal masses (≤ 4cm) on the length of hospital stay, measured in average stay in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the effect of IRE ablation of small renal masses (≤ 4cm) on the quality of life, assessed through SF-36 questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain score</measure>
    <time_frame>1 year</time_frame>
    <description>To asses the effect of IRE ablation of small renal masses (≤ 4cm), assessed through VAS score and analgesics use</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Irreversible electroporation (IRE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IRE is based on high current electric pulses, transferred between two or more placed needle electrodes. Charging the cell membrane causes holes in the cell membrane called &quot;nanopores&quot;, resulting in increased permeability of the cell and subsequent cell death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Irreversible Electroporation</intervention_name>
    <description>Guided by CT and accompanied by an external spacer for fixation, needle electrodes will be placed. The amount of probes and probe placement will be attuned for specific tumour size and location, granting 15mm between the electrodes with an active tip length of 15mm. IRE pulses with pulse intensity of 1500 V/cm will be delivered in 90 consecutive pulses of 90µs.</description>
    <arm_group_label>Irreversible electroporation (IRE)</arm_group_label>
    <other_name>Nanoknife</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Solid, enhancing mass on cross sectional imaging

          -  Signed informed consent

          -  Candidate for focal ablative therapy

        Exclusion Criteria:

          -  Irreversible bleeding disorders

          -  Inability/unwillingness to interrupt anticoagulation therapy

          -  Previous cryoablation, RFA or partial nephrectomy in affected kidney

          -  Anaesthesia Surgical Assignment (ASA), category ≤ IV

          -  ICD / pacemaker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Pilar Laguna Pes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center (AMC) Amsterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mara Buijs, MD</last_name>
    <phone>+31(0)205665793</phone>
    <email>m.buijs@amc.uva.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Pilar Laguna Pes, MD, PhD</last_name>
    <phone>+31(0)205666928</phone>
    <email>m.p.lagunapes@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Center (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mara Buijs, MD</last_name>
      <phone>+31(0)20-5665793</phone>
      <email>m.buijs@amc.uva.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, Roberts S, Evans P, Ball C, Haydon A. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011 May;22(5):611-21. doi: 10.1016/j.jvir.2010.12.014. Epub 2011 Mar 25.</citation>
    <PMID>21439847</PMID>
  </reference>
  <reference>
    <citation>Wendler JJ, Ricke J, Pech M, Fischbach F, Jürgens J, Siedentopf S, Roessner A, Porsch M, Baumunk D, Schostak M, Köllermann J, Liehr UB. First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial. Cardiovasc Intervent Radiol. 2016 Feb;39(2):239-50. doi: 10.1007/s00270-015-1200-6. Epub 2015 Sep 4.</citation>
    <PMID>26341653</PMID>
  </reference>
  <reference>
    <citation>Trimmer CK, Khosla A, Morgan M, Stephenson SL, Ozayar A, Cadeddu JA. Minimally Invasive Percutaneous Treatment of Small Renal Tumors with Irreversible Electroporation: A Single-Center Experience. J Vasc Interv Radiol. 2015 Oct;26(10):1465-71. doi: 10.1016/j.jvir.2015.06.028. Epub 2015 Aug 4.</citation>
    <PMID>26250855</PMID>
  </reference>
  <reference>
    <citation>Pech M, Janitzky A, Wendler JJ, Strang C, Blaschke S, Dudeck O, Ricke J, Liehr UB. Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study. Cardiovasc Intervent Radiol. 2011 Feb;34(1):132-8. doi: 10.1007/s00270-010-9964-1. Epub 2010 Aug 15.</citation>
    <PMID>20711837</PMID>
  </reference>
  <reference>
    <citation>van den Bos W, de Bruin DM, van Randen A, Engelbrecht MR, Postema AW, Muller BG, Varkarakis IM, Skolarikos A, Savci-Heijink CD, Jurhill RR, Zondervan PJ, Laguna Pes MP, Wijkstra H, de Reijke TM, de la Rosette JJ. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy. Eur Radiol. 2016 Jul;26(7):2252-60. doi: 10.1007/s00330-015-4042-3. Epub 2015 Oct 8.</citation>
    <PMID>26449559</PMID>
  </reference>
  <reference>
    <citation>van den Bos W, Scheffer HJ, Vogel JA, Wagstaff PG, de Bruin DM, de Jong MC, van Gemert MJ, de la Rosette JJ, Meijerink MR, Klaessens JH, Verdaasdonk RM. Thermal Energy during Irreversible Electroporation and the Influence of Different Ablation Parameters. J Vasc Interv Radiol. 2016 Mar;27(3):433-43. doi: 10.1016/j.jvir.2015.10.020. Epub 2015 Dec 17.</citation>
    <PMID>26703782</PMID>
  </reference>
  <reference>
    <citation>Wagstaff PG, de Bruin DM, van den Bos W, Ingels A, van Gemert MJ, Zondervan PJ, Verdaasdonk RM, van Lienden KP, van Leeuwen TG, de la Rosette JJ, Laguna Pes MP. Irreversible electroporation of the porcine kidney: Temperature development and distribution. Urol Oncol. 2015 Apr;33(4):168.e1-7. doi: 10.1016/j.urolonc.2014.11.019. Epub 2014 Dec 31.</citation>
    <PMID>25557146</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Dr. Prof. M.P. Laguna Pes</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

